TherapeuticsMD (TXMD) Company Report

TherapeuticsMD reported net income from continuing operations of $50 thousand, or $0.00 per basic and diluted common share, for the third quarter of 2025, with license revenue totaling $784 thousand.
As of September 30, 2025, the company's cash and cash equivalents were $7.1 million.
The company is continuing to evaluate strategic alternatives, which may include an acquisition, merger, or sale of assets, but there is no assurance of a transaction or a set timetable.
TherapeuticsMD transitioned to a pharmaceutical royalty company in December 2022, no longer engaging in research and development or commercial operations.

Nov 13, 2025, 1:54 AM

TherapeuticsMD Announces Third Quarter 2025 Financial Results

TXMD

Earnings

M&A

Revenue Acceleration/Inflection

TherapeuticsMD reported net income from continuing operations of $50 thousand for the third quarter of 2025, compared to a net loss of $567 thousand in the third quarter of 2024.
License revenue from continuing operations increased to $784 thousand for Q3 2025, up from $547 thousand in Q3 2024, driven by changes in sales of licensed products.
As of September 30, 2025, the company's cash and cash equivalents totaled $7.1 million.
The company is continuing to evaluate strategic alternatives, including potential acquisition, merger, or sale of assets, but there is no assurance of a transaction or its timing.